Clinical trials: Localization-related Epilepsy
Focal Epilepsy
Breathing Rescue for SUDEP Prevention
The purpose of this study is to precisely delineate human brain networks that modulate respiration and identify specific brain areas and stimulation techniques that can be used to prevent seizure-induced breathing failure.
- Trial name
- BreatheS (NCT05981755)
- Testing
- Breathing tasks, Brain mapping with stimulation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- The University of Texas Health Science Center, Houston
Focal Epilepsy, Generalized Seizure
Optimizing Therapy in Epilepsy Using Seizure Forecasts Via EEG and Wearables
Mayo Clinic is conducting a research study to test a new approach to managing seizures in people with epilepsy whose seizures have not been fully controlled with regular medications.
- Conditions
- Focal Epilepsy, Generalized Seizure, Drug Refractory Epilepsy
- Trial name
- FORESITE (NCT07012148)
- Testing
- UNEEG SubQ device, seizure forecasts, nasal diazepam, Preventative Medication (PM)
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Partial Seizure Disorder, Epilepsy
Topiramate as Adjunctive Therapy in Infants 1-24 Months for the Control of Partial Onset Seizures
The purpose of this study is to evaluate the tolerability, safety and efficacy of topiramate in infants with refractory partial onset seizures (POS).
- Conditions
- Partial Seizure Disorder, Epilepsy, Seizures
- Trial name
- NCT00113815
- Testing
- topiramate
- Where
- 94 sites in United States, Argentina and 21 more
- Volunteers
- 118 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Epilepsy, Epilepsies, Partial
A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures.
The purpose of this study is to evaluate the efficacy and safety of topiramate as add-on therapy in patients with difficult to control partial onset seizures who are taking one or two standard antiepileptic drugs.
- Conditions
- Epilepsy, Epilepsies, Partial, Seizures
- Trial name
- NCT00236691
- Testing
- topiramate
- Volunteers
- 188 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Focal Epilepsy
A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in…
- Trial name
- X-TOLE (NCT03796962)
- Testing
- XEN1101
- Where
- 95 sites in United States, Canada and 7 more
- Volunteers
- 325 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy
The purpose of this study is to assess the safety and feasibility of unilateral focused ultrasound thalamotomy in adults with focal onset epilepsy whose medicines are not working well.
- Trial name
- NCT03417297
- Testing
- High Intensity Focused Ultrasound
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of North Carolina, Chapel Hill
Focal Epilepsy, Tonic-Clonic Seizures
An Open-label Study of XEN1101 in Epilepsy
This study will evaluate the long term safety, tolerability, pharmacokinetics (PK), and efficacy of XEN1101 in subjects with Focal Onset Seizures (FOS) or Primary Generalized Tonic-Clonic Seizures (PGTCS) for the treatment of…
- Trial name
- X-TOLE4 (NCT05718817)
- Testing
- XEN1101
- Where
- 152 sites in United States, Argentina and 23 more
- Volunteers
- 880 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Epilepsy, Drug Resistant
Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy
Evaluation of the Efficacy and Safety of Deep Brain Stimulation of the Extreme Capsule (EC) for the Treatment of Drug-Resistant Epilepsy
- Trial name
- NCT06663124
- Testing
- EC-DBS ON
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xuanwu Hospital, Beijing
Epilepsy
The Role of Intracranial Electroencephalography (IEEG) in the Localization of Epileptogenic Zones (EZ) and Its Relationship With Prognosis
The mechanism of epilepsy pathogenesis is complex and not fully defined, and about 20-30% of patients with seizures that cannot be completely controlled by drugs become drug-resistant epilepsy.
- Trial name
- NCT05443958
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Epilepsy
Evaluation of Memory and Forgetting in Patients With Epilepsy
Drug-resistant focal epilepsy (DRFE) is frequently associated with complications of varying severity that impair patient's quality of life.
- Trial name
- EPIMNESIE (NCT04924933)
- Testing
- Computerised associative memory task using abstract words and landscape photographs
- Where
- France
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Epilepsy, Focal Epilepsy
Assessment of Patients With Drug-resistant Temporal Lobe Epilepsy With EEG Extended With Intra-auricular Electrodes
The study aims to evaluate the effectiveness of long-term video EEG monitoring using 10-20 electrodes extended with intra-auricular electrodes in locating the seizure onset zone and interictal epileptiform discharges (IEDs) in…
- Conditions
- Epilepsy, Focal Epilepsy, Drug Resistant Epilepsy
- Trial name
- NCT06366009
- Testing
- NaoX in-ear EEG system
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Przemyslaw Kunert
Epilepsy, Partial Seizures
Efficacy and Safety of Levetiracetam in Partial Seizures Control, With or Without Secondary Generalization
The purpose of this study is to determine whether levetiracetam as adjunctive therapy is effective in the treatment of partial seizures, with or without secondary generalization, associated with refractory focal epilepsy.
- Trial name
- Mozart (NCT01392768)
- Testing
- Levetiracetam
- Volunteers
- 126 people
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Focal Seizure, Epilepsy
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
This is a clinical research study for an investigational drug called RAP-219 in adult participants with focal seizures. This study is being conducted to determine if RAP-219 is safe and effective in reducing focal seizure…
- Conditions
- Focal Seizure, Epilepsy, Focal Epilepsy
- Trial name
- FOCUS 1 (NCT07563881)
- Testing
- RAP-219
- Where
- 18 sites in United States, South Korea
- Volunteers
- 333 people
- Sponsor
- Rapport Therapeutics Inc.
Partial Epilepsy
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic…
- Trial name
- NCT01397968
- Testing
- YKP3089
- Where
- 38 sites in United States, India and 2 more
- Volunteers
- 222 people
- Sponsor
- SK Life Science, Inc.
Partial Epilepsy
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial Epilepsy
The primary objective was to evaluate the efficacy of eslicarbazepine acetate (ESL) administered once daily at 1200 mg or 800 mg, compared with placebo as adjunctive therapy in patients with refractory partial epilepsy over a…
- Trial name
- NCT00957372
- Testing
- eslicarbazepine acetate, ESL - Open-label Extension (Part II)
- Where
- Portugal
- Volunteers
- 253 people
- Sponsor
- Bial - Portela C S.A.
Seizures, Epilepsy
A Study of the Safety of Topiramate Given in Combination With Other Medications in Adults and Children With Seizures
The purpose of this observational study is to evaluate the safety of topiramate when used in combination with other medications for seizures in adults and children.
- Trial name
- NCT00297349
- Testing
- Topiramate
- Volunteers
- 153 people
- Sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
Epilepsy
Long Term Study of the Safety of OXC XR as in Pediatric Epilepsy Subjects
Follow-on study to continue evaluation of the safety of OXC XR as adjunctive therapy in pediatric epilepsy
- Trial name
- NCT00918424
- Testing
- Oxcarbazepine Extended Release
- Where
- 6 sites in United States
- Sponsor
- Supernus Pharmaceuticals, Inc.
Epilepsy in Children, Focal Epilepsy
Novel Network Analysis of Intracranial Stereoelectroencephalography
Epilepsy is a disorder of the brain which is associated with disabling seizures and affects 100,000 people under 25. Many children with epilepsy also have a learning disability or problems with development.
- Conditions
- Epilepsy in Children, Focal Epilepsy, Epilepsy Intractable, Epilepsy, Focal
- Trial name
- NNAIS (NCT03916848)
- Testing
- Combined Micro-Macro SEEG Electrodes
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Great Ormond Street Hospital for Children NHS Foundation Trust
Localization-related Epilepsy, Partial Epilepsy
Improving Lesion Detection in Children With Magnetic Resonance Imaging (MRI)-Negative Partial Epilepsy Using Diffusion Tensor Imaging
Focal cortical dysplasia is one of the most common lesions responsible for medically refractory epilepsy in the pediatric population.
- Trial name
- NCT00894478
- Testing
- Diffusion Tensor Imaging (DTI), Magnetoencephalography
- Where
- Canada
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
Epilepsy
Extension Study Of Long-Term Safety And Efficacy Of Pregabalin As Monotherapy (Lyrica) In Patients With Partial Seizures
This study will evaluate the long term safety and efficacy of pregabalin (Lyrica) when administered by itself (without any other anti-epileptic medication) to epilepsy patients for the treatment of partial seizures.
- Trial name
- NCT00596466
- Testing
- pregabalin
- Where
- 44 sites in United States, Czechia and 2 more
- Volunteers
- 75 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.